Toward Neuroproteomics in Biological Psychiatry: A Systems Approach Unravels Okadaic Acid-Induced Alterations in the Neuronal Phosphoproteome

被引:8
作者
Oliveira, Joana Machado [1 ,2 ]
da Cruz e Silva, Cristovao B. [3 ]
Mueller, Thorsten [4 ]
Martins, Tania Soares [1 ,2 ]
Cova, Marta [1 ,2 ]
da Cruz e Silva, Odete A. B. [1 ,2 ]
Henriques, Ana Gabriela [1 ,2 ]
机构
[1] Univ Aveiro, Neurosci & Signalling Lab, Dept Med Sci, P-3810193 Aveiro, Portugal
[2] Univ Aveiro, Neurosci & Signalling Lab, Inst Biomed iBiMED, P-3810193 Aveiro, Portugal
[3] Lab Instrumentacao & Fis Expt Particulas LIP, Lisbon, Portugal
[4] Ruhr Univ Bochum, Cell Signaling Biochem Mol Biochem 2, Bochum, Germany
关键词
neuroproteomics; systems psychiatry; Alzheimer's disease; molecular targets; biomarker; Rattus norvegicus; PROTEIN PHOSPHATASE 2A; SRC FAMILY KINASES; A-BETA; UP-REGULATION; TAU; INHIBITION; PHOSPHORYLATION; TOOL; CYTOSKELETON; ACTIVATION;
D O I
10.1089/omi.2017.0108
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Neuroproteomics is an evolving field of postgenomic medicine, highlighting the convergence of psychiatry/ neurology and proteomics, yet compared with neurogenetics, it has received little attention. This study in rat primary neuronal cultures provides an example of a neuroproteomic approach relevant to the study of psychiatric disease pathophysiology, focusing on Alzheimer's disease. In this context, okadaic acid (OA) is routinely used in experimental designs to investigate phosphorylation-mediated events. It is a potent protein phosphatase (PP) inhibitor, particularly of PP1 and PP2A. Typically, a single protein and its phosphorylation level are monitored upon OA exposure. Although useful, this can be misleading as protein phosphorylation-mediated events involve complex signaling cascades and an array of kinases, phosphatases, and substrates. Bearing in mind the involvement of multiple pathways and cascade cross talk, this study employed a systems approach to analyze OA-induced molecular responses through PP inhibition. We showed that upon OA exposure, the recovery rate of 245 phosphoproteins significantly increased, while that of 75 significantly decreased. The prominent biological processes affected included anatomical structural development, transport, cell differentiation, and signal transduction. The associated phosphointeraction networks identified nodes representing OA-responsive phosphoproteins. Many of these are key players of signaling cascades relevant to a range of pathologies. In summary, the data presented results from a neuroproteomic preclinical study offering an array of phosphoproteins as potential targets for future diagnostic and therapeutic strategies in biological psychiatry. We note, however, the nonspecificity of targeting PPs themselves and emphasize the need for future neuroproteomic approaches toward systems psychiatry.
引用
收藏
页码:550 / 563
页数:14
相关论文
共 59 条
  • [1] Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of β-amyloid
    Ando, K
    Iijima, K
    Elliott, JI
    Kirino, Y
    Suzuki, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (43) : 40353 - 40361
  • [2] Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease
    Augustinack, JC
    Schneider, A
    Mandelkow, EM
    Hyman, BT
    [J]. ACTA NEUROPATHOLOGICA, 2002, 103 (01) : 26 - 35
  • [3] UniProt: the universal protein knowledgebase
    Bateman, Alex
    Martin, Maria Jesus
    O'Donovan, Claire
    Magrane, Michele
    Alpi, Emanuele
    Antunes, Ricardo
    Bely, Benoit
    Bingley, Mark
    Bonilla, Carlos
    Britto, Ramona
    Bursteinas, Borisas
    Bye-A-Jee, Hema
    Cowley, Andrew
    Da Silva, Alan
    De Giorgi, Maurizio
    Dogan, Tunca
    Fazzini, Francesco
    Castro, Leyla Garcia
    Figueira, Luis
    Garmiri, Penelope
    Georghiou, George
    Gonzalez, Daniel
    Hatton-Ellis, Emma
    Li, Weizhong
    Liu, Wudong
    Lopez, Rodrigo
    Luo, Jie
    Lussi, Yvonne
    MacDougall, Alistair
    Nightingale, Andrew
    Palka, Barbara
    Pichler, Klemens
    Poggioli, Diego
    Pundir, Sangya
    Pureza, Luis
    Qi, Guoying
    Rosanoff, Steven
    Saidi, Rabie
    Sawford, Tony
    Shypitsyna, Aleksandra
    Speretta, Elena
    Turner, Edward
    Tyagi, Nidhi
    Volynkin, Vladimir
    Wardell, Tony
    Warner, Kate
    Watkins, Xavier
    Zaru, Rossana
    Zellner, Hermann
    Xenarios, Ioannis
    [J]. NUCLEIC ACIDS RESEARCH, 2017, 45 (D1) : D158 - D169
  • [4] Role of protein phosphatase-2A and-1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain
    Bennecib, M
    Gong, CX
    Grundke-Iqbal, I
    Iqbal, K
    [J]. FEBS LETTERS, 2000, 485 (01) : 87 - 93
  • [5] The interplay between Src family kinases and receptor tyrosine kinases
    Bromann, PA
    Korkaya, H
    Courtneidge, SA
    [J]. ONCOGENE, 2004, 23 (48) : 7957 - 7968
  • [6] OKADAIC ACID ACTIVATES P42 MITOGEN-ACTIVATED PROTEIN-KINASE (MAP KINASE ERK-2) IN B-LYMPHOCYTES BUT INHIBITS RATHER THAN AUGMENTS CELLULAR PROLIFERATION - CONTRAST WITH PHORBOL 12-MYRISTATE 13-ACETATE
    CASILLAS, AM
    AMARAL, K
    CHEGINIFARAHANI, S
    NEL, AE
    [J]. BIOCHEMICAL JOURNAL, 1993, 290 : 545 - 550
  • [7] Self-Association of Okadaic Acid: Structural and Pharmacological Significance
    Cruz, Patricia G.
    Norte, Manuel
    Hernandez Creus, Alberto
    Fernandez, Jose J.
    Hernandez Daranas, Antonio
    [J]. MARINE DRUGS, 2013, 11 (06) : 1866 - 1877
  • [8] Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease
    Dhawan, Gunjan
    Combs, Colin K.
    [J]. JOURNAL OF NEUROINFLAMMATION, 2012, 9
  • [9] Okadaic acid, useful tool for studying cellular processes
    Fernández, JJ
    Candenas, ML
    Souto, ML
    Trujillo, MM
    Norte, M
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (02) : 229 - 262
  • [10] Protein Phosphatase 1 and Its Complexes in Carcinogenesis
    Figueiredo, Joao
    da Cruz e Silva, Odete A. B.
    Fardilha, Margarida
    [J]. CURRENT CANCER DRUG TARGETS, 2014, 14 (01) : 2 - 29